经典型霍奇金淋巴瘤中检查点CD47的表达
本研究用组织微阵列免疫组化检测两个队列共178例经典型霍奇金淋巴瘤(cHL)患者诊断活检中霍奇金和Reed-Sternberg(HRS)细胞的CD47表达及其与预后、PD免疫标志物和SIRPa+白细胞的相关性。队列I中HRS细胞CD47高表达者无事件生存期和总生存期均显著劣于低表达者,多变量校正后仍显著;队列II中高表达者无事件生存期缩短但多变量分析未保留统计学显著性。
要点
- 队列I中HRS细胞CD47高表达者无事件生存期(HR=5.57)和总生存期(HR=8.54)均显著劣于低表达者。
- 队列II中CD47高表达者无事件生存期HR=5.96(p=0.029),但多变量分析未保留统计学显著性。
- CD47高表达与SIRPa+白细胞及PD-1、PD-L1、PD-L2表达均无相关性。
核心结论
- 本研究加深了对CD47在cHL中作用的理解,正值CD47靶向治疗兴起之时。
研究设计与样本
- 对两个队列共178例cHL患者的诊断活检组织微阵列进行CD47和SIRPa抗体免疫组化检测。
- 队列I纳入136例患者,其中HRS细胞CD47高表达48例、低表达88例。
- 队列II纳入42例患者。
主要发现
- 队列I中HRS细胞CD47高表达者较低表达者无事件生存期显著更差(HR=5.57;95%CI 2.78-11.20;p<0.001),总生存期亦显著更差(HR=8.54;95%CI 3.19-22.90;p<0.001)。
- 队列I中校正已知预后因素的多变量Cox回归后生存结果仍具统计学显著性。
- 队列II中HRS细胞CD47高表达者无事件生存期更短(HR=5.96;95%CI 1.20-29.59;p=0.029),总生存期HR=5.61(95%CI 0.58-54.15;p=0.136),多变量分析未保留统计学显著性。
- CD47高表达与SIRPa+白细胞及PD-1、PD-L1、PD-L2表达均无相关性。
局限性
- 队列II中CD47高表达与总生存期的关联未达统计学显著(HR=5.61;95%CI 0.58-54.15;p=0.136),且多变量分析未保留统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The glycoprotein CD47 regulates antiphagocytic activity via signal regulatory protein alpha (SIRPa). This study investigated CD47 expression on Hodgkin and Reed-Sternberg (HRS) cells in the classical Hodgkin lymphoma (cHL) tumour microenvironment and its correlation with prognosis, programmed-death (PD) immune markers, and SIRPa+ leukocytes. We conducted immunohistochemistry with CD47 and SIRPa antibodies on diagnostic biopsies (tissue microarrays) from cHL patients from two cohorts (n = 178). In cohort I (n = 136) patients with high expression of CD47 on HRS cells (n = 48) had a significantly inferior event-free survival [hazard ratio (HR) = 5.57; 95% confidence interval (CI), 2.78-11.20; p < 0.001] and overall survival (OS) (HR = 8.54; 95% CI, 3.19-22.90; p < 0.001) compared with patients with low expression (n = 88). The survival results remained statistically significant in multivariable Cox regression adjusted for known prognostic factors. In cohort II (n = 42) high HRS cell CD47 expression also carried shorter event-free survival (EFS) (HR = 5.96; 95% CI, 1.20-29.59; p = 0.029) and OS (HR = 5.61; 95% CI, 0.58-54.15; p = 0.136), although it did not retain statistical significance in the multivariable analysis. Further, high CD47 expression did not correlate with SIRPa+ leukocytes or PD-1, PD-L1 and PD-L2 expression. This study provides a deeper understanding of the role of CD47 in cHL during an era of emerging CD47 therapies.
引用
- Gholiha AR, Hollander P, Löf L, et al. Checkpoint CD47 expression in classical Hodgkin lymphoma. Br J Haematol. 2022. PMID: 35301709. doi:10.1111/bjh.18137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。